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Background: Diabetes mellitus is affecting more than 300 million people worldwide. Current treatment strategies
cannot prevent secondary complications. Stem cells due to their regenerative power have long been the attractive
target for the cell-based therapies. Mesenchymal stem cells (MSCs) possess the ability to differentiate into several
cell types and to escape immune recognition in vitro. MSCs can be differentiated into insulin-producing cells (IPCs)
and could be an exciting therapy for diabetes but problems like poor engraftment and survivability need to be
confronted. It was hypothesized that stromal cell derived factor- 1alpha (SDF-1alpha) will enhance therapeutic
potential of stem cell derived IPCs by increasing their survival and proliferation rate.
Methods: Novel culture conditions were developed to differentiate bone marrow derived mesenchymal stem cells
(BMSCs) into IPCs by using endocrine differentiation inducers and growth factors via a three stage protocol. In
order to enhance their therapeutic potential, we preconditioned IPCs with SDF-1alpha.
Results: Our results showed that SDF-1alpha increases survival and proliferation of IPCs and protects them from
glucotoxicity under high glucose conditions in vitro. SDF-1alpha also enhances the glucose responsive insulin
secretion in IPCs in vitro. SDF-1alpha preconditioning reverses hyperglycemia and increase serum insulin in drug
induced diabetic rats.
Conclusions: The differentiation of BMSCs into IPCs and enhancement of their therapeutic potential by SDF-1alpha
preconditioning may contribute to cell based therapies for diabetes.
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Diabetes mellitus (DM), a life threatening single-cell meta-
bolic disorder, is defined by the presence of hyperglycemia
due to damage or faulty pancreatic beta cells. Type 1 dia-
betes results from T-cell mediated autoimmune demo-
lition of β-cells [1]. At least 285 million people were
affected from diabetes in 2010 worldwide and this number
is increasing day by day [2]. The treatment of the absolute
insulin deficiency resulting from Type 1 diabetes is very* Correspondence: m_awan_tariq@hotmail.com
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reproduction in any medium, provided the orchallenging. Despite significant advances in the manufac-
ture, modification and delivery of insulin, insulin therapy
remains relatively risky and cannot prevent secondary
complications. Islet-transplantation, the most successful
treatment of DM, is hampered due to issues such as;
severe shortage of pancreas donors, low islet isolation suc-
cess rate, difficulty in maintaining an insulin-free status
and the side effects of anti-rejection drugs [3,4]. Thus it is
the need of hour to look for new strategies to generate
pancreatic beta cells either in vitro or in vivo. An attractive
approach for reversing diabetes is beta cell regeneration
from adult stem cells. By using beta cells from a patient’s
own adult stem cells, immunosuppression can be avoided.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are able to differentiate into a number of different cell
types of mesodermal lineages such as adipocytes, osteo-
blasts and other mesodermal cells [5,6]. MSCs can be
differentiated into insulin producing cells (IPCs) and their
possible therapeutic potential for diabetes depends upon
this differential ability [7-9]. IPCs express the pancreatic
β-cells developmental genes such as pancreatic and duo-
denal homeobox-1 (PDX-1) or functional genes such as
insulin, and glucagon [8-11] and secrete insulin in re-
sponse to glucose that reverses hyperglycemia in drug-
induced diabetic mice [8,9,12]. The remedial use of MSCs
is limited at present due to several problems such as poor
engraftment, limited differentiation in host tissue [13] and
differentiation of MSCs into unwanted lineages [14] by a
variety of factors [15].
The enhancement of survival and proliferation of
MSCs by growth factors has been extensively studied.
The majority of growth factors is pleiotropic and
changes motility, proliferation, morphogenesis and sur-
vival of cells. Glucose homeostasis is regulated by several
polypeptides such as insulin, adiponectin, glucagon-like
peptide–1 (GLP-1), and many others making them at-
tractive candidates for the treatment of diabetes [16].
Many different strategies have been employed to induce
the differentiation of IPCs from stem cells in vitro.
These strategies have involved supplementation of differ-
entiation medium with a variety of induction and growth
factors, such as nourished ES cells with all-trans retinoic
acid [17], betacellulin, activin A [18] and vitamin deriva-
tives such as nicotinamide [19]. A number of studies have
highlighted the role of GLP-1, a known anti-diabetic
agent, in β cell development, function, proliferation and
neogenesis [20,21]. Stromal cell-derived factor-1 (SDF-1),
a chemokine known to express in stromal tissues in mul-
tiple organs, promotes β-cell survival in RIP-SDF-1 trans-
genic mice and MIN-6 and INS-1 clonal beta-cells by the
activation of Akt signaling pathway and attenuates dia-
betes in streptozotocin (STZ) induced mice [22]. The
activation of Akt signaling pathway have cell survival, cell
proliferating and anti-apoptotic roles. SDF- 1/CXCR4 axis
modulates cell migration and cell survival during develop-
ment and tissue remodeling [23]. Moreover, SDF-1α
/CXCR4 is an obligatory component in the maintenance of
pancreatic duct cell-survival, cell-proliferation and migra-
tion during pancreatic organogenesis and regeneration in
pancreatic acinar cells [24]. The PI3K/Akt pathway is an
important mediator of cell survival in many cell types such
as beta cells [25-27] and PI3K/Akt signaling has been
shown to play a central role in pancreatic regeneration [28].
To make use of the therapeutic potential of SDF-1α
pre-conditioning in IPCs survival and proliferation, we hy-
pothesized that SDF-1α pre-conditioning augments IPCs
survival and may reverse hyperglycemia.Methods
Animals care
The current study was carried according to the Guide
for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication
No. 85–23, revised 1996). All animals were treated
according to the procedures approved by the Institu-
tional Review Board (IRB) at the National Center of
Excellence in Molecular Biology, Lahore, Pakistan.
Animals
Inbred Sprague–Dawley (SD) rats, aged 8–16 weeks,
were used in this study as streptozotocin can easily
cause diabetes in these animals [29]. Rats were placed in
a special room where the temperature was kept at 22°C
and the light was on a 12 hr dark / light cycle through-
out the year.
Isolation and culture of rat BM-derived MSCs
Rat BMSCs were isolated and cultured as previously de-
scribed [30]. In brief, bone marrow was isolated from
the femur and tibia of 3–4 months old SD rats. After
removing epiphyses and gaining access to the marrow
cavities, whole BM was flushed out from bones. The
resulting cell suspension was centrifuged and the cell
pellet was re-suspended in DMEM-LG supplemented
with 10% fetal bovine serum (FBS) and 1% antibiotic
(100 μg/ml streptomycin and 100 U/ml penicillin). The
cells were plated in tissue culture flask and placed in incu-
bator having 5% CO2 and 95% air at 37°C. The medium
was then changed after every three days. When cells were
80% confluent, they were sub-cultured in a ratio 1:3.
Differentiation of BMSCs into IPCs
When BMSCs at 3rd passage were 70%-80% confluent,
they were differentiated into insulin producing cells (IPCs)
by a three stage protocol as follows. Stage 1: The cells
were induced with DMEM-LG containing 0.5 mM/L 2-
mercaptoethanol, 10 mM/L nicotinamide and 5% FBS
for 2 days. Stage 2: The pre-induced cells were further
treated with serum free DMEM high glucose (DMEM-
HG) medium containing 0.5 mM/L 2-mercaptoethanol,
10 mM/L nicotinamide and 10 ng/ml activin A for 10
hours. Stage 3: The cells were cultured for an additional 8
days in new DMEM-HG medium containing 20 ng/ml
β-fibroblast growth factor (bFGF, Sigma), 20 ng/ml epider-
mal growth factor (EGF, Sigma), 2% B27 (Gibco), 2 mM/L
L-glutamine (Hyclone Laboratories), 10 mM/L nicotina-
mide and 50 ng/ml GLP-1.
Identification of IPCs by dithizone (DTZ) staining
Presence of IPCs in culture can be identified with Zn-
chelating agent dithizone which binds with free Zn2+
present in these cells. The stock solution was prepared
Table 1 Primer sequences of various genes
Genes Primer sequences
Insulin 1 Forward 5’-CAGTTGGTAGAGGGAGCAG-3’
Reverse 5’-CAGTTGGTAGAGGGAGCAG-3’






Nkx 6.1 Forward 5’-ATGGGAAGAGAAAACACACCAGAC-3’
Reverse 5’-TAATCGTCGTCGTCCTCCTCGTTC-3’
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stored at −20°C until used. The working solution of
DTZ was prepared by bringing stock solution to room
temperature. 10 μl working DTZ solution was added to
culture medium and incubated for 30 min at 37°C. The
crimson-red-stained clusters were observed under a
microscope.
Immunocytochemical analysis for pancreatic
developmental markers in IPCs
To confirm the differentiation of BMSCs into IPCs, cul-
tured IPCs were incubated with primary antibodies
specific to insulin, Ngn3 and Pdx-1 and then treated to
respective secondary antibodies. Nuclei were counter-
stained with DAPI. At least six randomly high power
fields were selected from each slide. Fluorescent images
were obtained with an Olympus IX 51 and BX 61 micro-
scopes equipped with digital cameras (Olympus).
RT-PCR analysis for expression of genes of pancreatic
development in IPCs
Total cellular RNA was extracted from BMSCs, IPCs and
pancreatic tissue by using TRIZOL reagent (Invitrogen).
cDNA was synthesized using total RNA by Revert Aid H
Minus first strand cDNA synthesis kit (Fermentas; Cat#
K1632). Following PCR conditions were used: 1 cycle at
94°C for 4 min: 35 cycles at (94°C for 45 s, annealing temp
for 45 s and 72°C for 60 s) and 1 extended cycle at 72°C
for 10 min. The PCR products were size-fractionated by
2.0% agarose gel electrophoresis. The oligonucleotide
sequences specific for the selected genes are presented in
Table 1.
Preconditioning of IPCs
At day 11, BMSCs derived IPCs were preconditioned
with SDF-1α. IPCs were incubated in normal DMEM-
HG containing 50 ng/ml GLP-1, 10% FBS and 50 ng/ml
SDF-1α for 48 hours in CO2 incubator and rinsed for 10
min with normal medium for further in vitro and in vivo
studies.
In vitro experiments
Three experimental groups were assigned as follows: (I)
Normal BMSCs at 3rd passage; (II) Non-preconditioned
IPCs incubated in normal DMEM-HG containing 50 ng/ml
GLP-1 and 10% FBS; (III) SDF-1α preconditioned IPCs
incubated in normal DMEM-HG containing 50 ng/ml
GLP-1, 10% FBS and 50 ng/ml SDF-1α. All groups were
incubated for 48 hours in CO2 incubator and rinsed for 10
min with normal medium. To compare the effect of differ-
ent glucose concentrations on above mentioned groups, a
total of 2 × 104 cells/well were cultured in 24-well plates in
the DMEM containing 5.5 mM/L, 17 mM/L and 33 mM/L
glucose for 2 days.Measurement of lactate dehydrogenase (LDH) and cell
viability
The cell viability was evaluated after treating with differ-
ent concentrations of glucose by the trypan blue dye-
exclusion method. Cell supernatant was analyzed for
LDH activity using LDH based in vitro toxicological kit
TOX7 (Sigma) and taking absorbance at 490 nm and a
reference wavelength of 690 nm to obtain sample signal
(OD490-OD690).
Cell proliferation assay
The cells treated with different glucose concentrations
were incubated for 2–3 hrs with 40 μl/well MTT (3-(4,
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium brom-
ide) reagent (Sigma-Aldrich) having concentration of
5 mg/ml. The medium was aspirated and the cells were
suspended in dimethyl sulfoxide. Absorbance of the
formazan product which is directly proportional to the
number of living cells was measured by an ELISA plate
reader at 570 nm and a reference wavelength of 630 nm
to obtain sample signal (OD570-OD630).
ELISA for insulin
To determine whether SDF-1α preconditioning causes an
increase in insulin release from IPCs, an enzyme-linked
immunoassay (ELISA) was used to quantify insulin levels
in various groups after incubating with different glucose
concentrations for 2 days. Cells were incubated with
freshly prepared Krebs Ringer bicarbonate HEPES (KRBH)
buffer supplemented with 3.8 mM/L glucose for 2 hrs at
37°C. Then KRBH buffer supplemented with 5.5 mM/L,
17 mM/L and 33 mM/L glucose was added to tissue cul-
ture plates and incubated for 3 hrs at 37°C. Supernatant
was collected and insulin released was determined by
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luated. The results were compared with a standard curve
constructed with murine insulin (each assay carried out in
triplicate for each group).In vivo experiments
Induction of diabetes
Diabetes was induced in 20 female SD rats at 8–16
weeks of age by intraperitoneal injection of 40 mg/kg
of streptozotocin (STZ) in cold sodium citrate buffer
(pH 4.5). Control rats were treated with citrate buffer
only. Blood glucose levels were measured by using
Roche ACCU-CHEK glucometer. Stable blood glucose
levels ranging between 300–520 mg/dl developed in rats
one week later while blood glucose levels of normal rats
were in range of 75–125 mg/dl.PKH26-labelling of cells
Prior to transplantation in the kidney capsule, IPCs were
labeled with PKH26 (Sigma, Product no.: PKH26-GL)
according to manufacturer’s protocol. This lipophilic dye
PKH26 binds irreversibly to the cell membranes and
serves an important marker for tracking stem cells in
the transplanted tissue.Transplantation
Diabetic rats were divided into three groups (n = 12)
after showing consistent hyperglycemia (blood glucose >
300 mg/dl) for at least three measurements. The diabetic
rats of 1st group received IPCs pre-conditioned with
SDF-1α, 2nd group received IPCs only and 3rd group
was injected with serum free medium. Rats were anes-
thetized, shaved from left dorsal side and cleaned. A
small incision was made on the left flank of the rat and
the kidney was exposed. A total of 3×106 labeled cells
were transplanted into the left kidney capsule at three
different sites.Measurement of blood glucose and serum insulin
The blood glucose levels were monitored at every third
day by using AccuChek glucometer for 30 days after
transplantation. The blood samples from transplanted
rats were collected at day 7, 14, 21 and 28. Serum was
isolated from these samples and insulin was measured
by ELISA.Organ procurement and processing
Rats were euthanized at 28 days after cell transplantation.
For cryo sectioning, the excised kidney and pancreatic
tissues were embedded in Tissue-Tek OCT (Sakura
Torrance, CA, USA). 5 um thick tissue sections were cut
with the help of cryostat (Microm) at -20C°.Homing of transplanted cells
To assess the homing of transplanted IPCs, the sections
were prepared from frozen tissues. Sections were exam-
ined under fluorescent microscope Olympus BX61 using
standard filter setup for TRITC (PKH26). The stained
sections were digitally imaged using a computerized
image-analysis system. The number of PKH 26 positive
cells was counted in six randomly selected areas.
Immunohistochemical analysis for Ki-67 for determination
of proliferating cells
The proliferating cells in pancreata of diabetic rats after
transplantation were seen by staining with immPRESS
Reagent (Vector Labs) using manufacturer’s protocol.
Briefly, air dried, acetone fixed frozen sections were
washed with PBS and incubated for 20 min with 2.5%
normal horse blocking serum. Sections were incubated
with primary antibodies specific to Ki-67 and treated
with ImmPRESS reagent. Sections were incubated in
peroxidase substrate solution until sufficient stain deve-
loped. Nuclei were counter-stained with eosin. At least six
randomly high power fields were selected from each slide.
Fluorescent images were obtained with an Olympus BX61
microscope equipped with digital cameras (Olympus).
Statistical analysis
Experiments were performed in quadruplicate and re-
peated at least three times. All values are expressed as
mean ± standard error of the mean (SEM). Statistical sig-
nificance was analyzed using one way ANOVA followed
by Bonferroni testing through Graphpad Prism 5 software.
A p-value ≤ 0.05 was considered statistically significant.
Results and discussion
In vitro study
Differentiation of BMSCs into beta like IPCs
At day 5 of induction, BMSCs started to form sphere-
shaped clusters which attained their maximum size and
maximal number at day 11 while control BMSCs which
were not induced did not show any cluster formation
(Figure 1a). Many cells in the culture induced with dif-
ferent reagents and growth factors stained crimson red
with DTZ (Figure 1b) indicating the differentiation of
BMSCs into IPCs. Control BMSCs were not stained.
The culture induced with different reagents and growth
factors expressed transcripts of insulin-I and insulin-II
along with transcription factors Pdx-1, Ngn3, Nkx 6.1
and Nkx 6.2 (Figure 2b) at the completion of treatment.
Immunostaining of induced cultured cells showed many
insulin positive cells (Figure 2a) while the nuclei of dif-
ferentiated IPCs expressed transcription factors Ngn3
and PDX-1 (Figure 2a). Treatment of BMSCs with
insulin-promoting factors such as nicotinamide, high
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and GLP-1 differentiate them into IPCs. Nicotinamide, a
poly(ADP-ribose) synthetase inhibitor, is a well-known
inducer to differentiate stem cells into IPCs and protect
cells from glucotoxicity induced by exposure to high
glucose [9,12,19,31]. Tang et al., (2004) considered high
glucose concentration as a potent inducer for pancreatic
islet differentiation [32]. But Sun et al., (2007) reported
that high glucose alone could not induce bone marrow-
derived MSCs to IPCs [9]. Activin A, a member of the
transforming growth factor-beta (TGF-β) super-family,
regulated neogenesis of β-cells in vivo [33] and induced
ESCs into pancreatic β-cells [18]. GLP-1, an incretin
hormone, used to convert intestinal epithelial cells into
IPCs [34] and also differentiated BMSCs into IPCs [35].
Neshati et al., (2010) indicated that treatment of MSCs
with high glucose, nicotinamide and 2-mercaptoethanol
differentiated them into IPCs [36]. In the present study,
we combined the previously used endocrine differenti-
ation inducers in a novel way to differentiate BMSCs
into IPCs.
The pancreas develops under a cascade of gene activa-
tion events controlled by transcription factors including
PDX-1, Ngn3, NeuroD1, PAX-6, PAX-4, Nkx2.2, Nkx6.1
and so on [37,38]. Nkx-6.1 is exclusively expressed in
the islets of Langerhans in differentiating and matureFigure 1 Morphology and dithizone staining of differentiation of MSC
into IPCs days 0, 3 and 11. Undifferentiated (left) and differentiated (right).
and matured towards day 11. b) Detection of Insulin producing cells after
dithizone. Differentiated MSCs-derived IPCs at day 11 were distinctly stainebeta-cells. The presence of PDX-1 is required for the ex-
pression of Nkx-6.1 as well as other pancreatic beta cell
specific genes, including insulin and both Nkx 6.1 and
Nkx 6.2 activity is required for α- and beta-cell
development in the pancreas [39]. Nkx 6.1 regulates the
expression of Nkx 6.2 [39]. Therefore, in vitro differen-
tiated IPCs should express genes of the pancreatic deve-
lopmental transcription factors mentioned above along
with the genes for insulin I and insulin II.
In this study, the expression of PDX1 observed at day 3
(Figure 2b) may have initiated a cascade of events that
leads towards insulin transcription as PDX-1 controls the
transcription of endocrine progenitor cells. PDX-1 con-
tributes to specification of endocrine progenitors both by
regulating expression of Ngn3 directly and by participa-
ting in a cross-regulatory transcription factor network
during early pancreas development [40]. Following PDX-1
gene activation, the pancreatic transcriptional activation of
genes such as Ngn3 occurs [41,42]. In our study, Ngn3
stably expressed at day 11 (Figure 2b). Ngn3 is required
for the development of the four endocrine cell lineages
(alpha, beta, delta and PP) of the pancreas [43]. In our
study both Nkx 6.1 and Nkx 6.2 were expressed during
the differentiation of BMSCs into IPCs. The expression of
the transcripts of the major pancreatic hormones insulin-
1 and insulin-2 further confirmed the differentiation ofs into IPCs. a) Morphological changes during differentiation of MSCs
Formation of islet-like clusters in differentiated group started at day 3
differentiation. At day 11, cells were stained with zinc-chelating agent,
d crimson-red by DTZ.
Figure 2 Expression of pancreas specific hormones and transcription factors in differentiated IPCs at day11. a) Immunofluorescence
analysis in differentiated IPCs at day11 of Pdx-1 (10X), Ngn3 (20X) and Insulin (20X). b) Reverse transcriptase analysis. Lane 1) BM-derived MSCs at
passage-3 before the start of treatment at day 0 Lane 2) BM-derived MSCs after pre-induction after stage-2 at day 3 Lane 3) Differentiated BM-
derived MSCs after stage-3 at day 11 Lane 4) Pancreas as positive control.
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entiation (Figure 2b) was similar to that of pancreatic
tissue.
SDF-1α preconditioning enhances cell viability and
proliferation of IPCs under high glucose conditions
This study demonstrated for the first time the effect of
SDF-1α pre-conditioning on IPCs in vitro as well as
in vivo. Differentiated IPCs were pre-conditioned with
SDF-1α. Cell viability evaluated by trypan blue exclusion
assay showed marked increase in viable cells in SDF-1α
preconditioned group compared with the control and
non-preconditioned group (Figure 3a). To assess cell pro-
liferation in the differentiated IPCs after pre-conditioning
with SDF-1α, MTT assay was performed. IPCs pre-
conditioned with SDF-1α showed better proliferation
(1.21 ± 0.041) than non-preconditioned IPCs (1.05 ±
0.027) under high (33 mM/L) glucose concentration
(Figure 3c). Our results demonstrated that SDF-1α pre-
conditioning of IPCs significantly enhanced cell viability
as compared to control BMSCs and non-preconditioned
IPCs under low as well as high glucose concentrations
(Figure 3a) and showed better proliferation under different
glucose concentrations (Figure 3c). Previous studies
showed that SDF-1α promotes pancreatic beta-cell sur-
vival by the activation of Akt signaling pathway and has
cell proliferating, cell survival, anti-apoptotic roles [22],
chemotactic properties and facilitates the homing of
MSCs in various tissues [44,45].SDF-1α preconditioning protects IPCs from glucotoxicity
These findings were further confirmed by LDH release
assay which revealed that preconditioning of IPCs
with SDF-1α extensively lessened the cyto-pathic effects
induced by high glucose in vitro (Figure 3b). This indi-
cated that pre-conditioning reduces glucotoxicity caused
by high glucose in vitro. Therefore, these results are in
accordance with other studies conducted to explore bio-
logical effects of SDF-1α in development of pancreas
and in cell based therapies for other organs [41,44,45].
Futhur more, pre-conditioning of MSCs with growth
factors etc. plays a major role in augmenting resistance
of MSCs to stress due to injury or disease in vitro or
in vivo [46].
SDF-1α preconditioned IPCs are glucose responsive
The pancreatic β-cells possess the ability to regulate the
secretion of insulin in a glucose dependent manner.
The glucose-responsive insulin release by SDF-1α pre-
conditioned IPCs and non-preconditioned IPCs was ana-
lyzed in vitro by ELISA after exposing to high glucose.
Both BM-derived non-preconditioned IPCs and SDF-1α
pre-conditioned IPCs secreted insulin in response to
high glucose challenge in a glucose-regulated manner
but SDF-1α pre-conditioned IPCs distinctly showed
higher rate of insulin release (67.3 ± 4.9 Vs 60 ± 5.4) and
(116.6 ± 5.9 Vs 85.7 ± 6.5) at 17 and 33 mM/L glucose
concentrations respectively (Figure 3d) indicating that
SDF-1α pre-conditioning had positive impact on the
Figure 3 Effect of SDF-1α preconditioning on IPCs under different glucose concentrations in vitro. a) The number of viable cells is plotted
in relevance with normal BM-derived MSCs. There is a marked increase in cell survivability in pre-conditioned group than control and non pre-
conditioned groups (n = 6). b) Cyto-protective effect of SDF-1α pre-conditioning on IPCs. Pre-conditioned IPCs showed low level of LDH
compared to the control and non pre-conditioned groups indicating less cellular injury. c) Effect of SDF-1α pre-conditioning on cell proliferation
under different glucose concentrations. Pre-conditioned IPCs showed higher rate of proliferation as compared to the control and non pre-
conditioned groups. d) Glucose responsive insulin release by SDF-1α pre-conditioned IPCs. The IPCs were exposed to either 5.5 mM/L, 17 mM/L
or 33 mM/L glucose. Insulin released from the IPCs upon glucose induction was determined by ELISA. The experiments were performed in
triplicates and repeated three times. All values were expressed as mean ± SEM.
Tariq et al. Journal of Translational Medicine 2013, 11:115 Page 7 of 10
http://www.translational-medicine.com/content/11/1/115glucose dependent insulin release. Control BMSCs cul-
tured in normal medium showed no significant release
of insulin in different glucose concentrations.
In vivo studies
Reversal of hyperglycemia in STZ-induced diabetic rats
To observe the role of SDF-1α pre-conditioning on IPCs
in vivo, 3 × 106 SDF-1α pre-conditioned IPCs were
transplanted in left kidney capsule of the STZ-induced
diabetic rats (n = 8). The control group (n = 8) was
injected with serum free medium only. The blood
glucose level of transplanted rats was monitored for 28
days after transplantation. The results showed that the
glucose levels in the rats transplanted with SDF-1α pre-
conditioned IPCs (173 ± 10.4 mg/dl) decreased signifi-
cantly (Figure 4a) as compared to diabetic control group
(482 ± 26.8 mg/dl). The decrease in glucose levels intransplanted group was significant. The control diabetic
rats remained hyperglycemic throughout the study period.
Increase in serum insulin levels of transplanted diabetic rats
The functionality of SDF-1α pre-conditioned IPCs in vivo
was assessed by serum insulin level measurement by
ELISA. The results demonstrated that the insulin levels in
the SDF-1α pre-conditioned IPCs group was increased
from (0.317 ± 0.01) at day 10 to (0.47 ± 0.024) at day 20.
This increase was significant as compared to diabetic
control group (0.032 ± 0.009) at day 10 and (0.027 ± 0.024)
at day 20 (Figure 4b).
SDF-1α preconditioning enhances homing of IPCs in
diabetic kidney
The homing of transplanted IPCs was assessed by track-
ing PKH-26 labeled IPCs in left kidney, the site of
Figure 4 Functional analysis after SDF-1α preconditioned IPCs transplantation in vivo. a) Blood glucose levels after SDF-1α Pre-
conditioned IPCs transplantation. Glucose levels were monitored by tail-vein blood at under random conditions. b) Serum Insulin Levels after
Transplantation of SDF-1α Pre-conditioned IPCs. The serum insulin measured by ELISA of serum samples at days mentioned. The day 0 indicates
the day of cell transplantation. All values are expressed as mean ± SEM. c) Homing of transplanted SDF-1α Pre-conditioned IPCs in left Kidney at d
10 in control diabetic rats and SDF-1α preconditioned IPCs transplanted rats.
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beled IPCs in the sections of left kidneys of recipient
rats (Figure 4c).
Ki-67 staining for the determination of proliferating cells
The Ki-67 staining of pancreatic sections of rats trans-
planted with SDF-1α pre-conditioned IPCs revealed many
Ki-67 positive cells in pancreas. There were no Ki-67 posi-
tive cells in the pancreatic sections of control diabetic rats
which received only serum free medium (Figure 5). ThisFigure 5 The Ki-67 staining of pancreatic sections of rats transplanted w
in pancreas after transplantation of SDF-1α preconditioned IPCs in control diaconfirms the presence of proliferating cells in rats trans-
planted with SDF-1α preconditioned IPCs.
Conclusions
Therapeutic potential of stem cells has made stem cell
research one of the most promising fields in biomedical
research. There is a growing concern to find alternative
sources of β-cells to cure diabetes. MSCs have emerged
as a new cell therapeutic tool in regenerative medicine.
We in this study with slight difference from many othersith SDF-1α preconditioned IPCs. Proliferating cells stained with Ki-67
betic rats (a) and SDF-1α preconditioned IPCs transplanted rats (b).
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IPCs but this study demonstrated for the first time the
effect of SDF-1α pre-conditioning on IPCs in vitro as
well as in vivo. SDF-1α enhances their survival and
proliferation, lowers apoptosis in vitro and reverses
STZ-induced diabetes in rats. The results demonstrated
that the insulin secreted by SDF-1α pre-conditioned
IPCs after induction with high glucose was glucose
responsive. In vivo study demonstrated reversal of hyper-
glycemia and an increase in serum insulin levels in the
rats transplanted with SDF-1α pre-conditioned IPCs.
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